Angela Hwang - 10 May 2023 Form 4 Insider Report for PFIZER INC (PFE)

Reporting relationship: President, Global Biopharma
Issuer ticker: PFE
Reported as of: 10 May 2023
Net transaction value: +$1,300,017
SEC form: 4
Accepted by SEC: 11 May 2023, 18:46:49 UTC
Prior SEC filing: 05 May 2023
Next SEC filing: 03 May 2024
Source filing: View source filing
Reporting owner signature: Susan E. Grant, by power of atty., for Angela Hwang

Key filing fact

Angela Hwang filed Form 4 for PFIZER INC (PFE) on 11 May 2023.

Key facts

This page summarizes Angela Hwang's Form 4 filing for PFIZER INC (PFE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 May 2023, 18:46.

Change

Previous filing in this sequence was filed on 05 May 2023.
Current net transaction value: +$1,300,017.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PFE transaction Derivative

Phantom Stock Units SSP

Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities

Transaction value: $1,300,017
Shares: +33,943
Change %: +97%
Price: $38.30
Shares after: 69,046
Date: 10 May 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 33,943
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each unit represents one phantom share of common stock.

Footnote F2

This transaction constitutes an intra-plan transfer to acquire Pfizer stock units in the Pfizer stock unit fund under the Pfizer Inc. Supplemental Savings Plan.

Footnote F3

These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.